Healthcare / Drug Manufacturers - GeneralShanghai
$14.88
-0.21 (-1.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $191.6M · quality 79.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.3B
P/E
106.3x
↑EV/EBITDA
45.4x
↑ROE
3.9%
↑Gross Margin
67.6%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.6%
FCF CAGR
-7.8%
FCF margin
14.0%
FCF / Net income
3.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.37B · net income $63.0M · FCF $191.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.37B | $1.37B | $1.22B | $1.28B | $1.13B |
| Net Income | $63.0M | $63.0M | $74.5M | $90.1M | $-250.0M |
| EBITDA | $153.5M | $153.5M | $140.8M | $163.3M | $-200.1M |
| EPS | 0.13 | 0.13 | 0.15 | 0.18 | -0.51 |
| Gross Margin | 67.6% | 67.6% | 73.6% | 72.9% | 67.5% |
| Operating Margin | 10.1% | 10.1% | 15.2% | 12.2% | -14.7% |
| Net Margin | 4.6% | 4.6% | 6.1% | 7.0% | -22.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.05 | 0.19 | 0.31 |
| Current Ratio | 2.20 | 2.20 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $191.6M | $191.6M | $103.6M | $213.0M | $244.8M |
| Returns | |||||
| ROE | 3.9% | 3.9% | 4.7% | 6.0% | -17.7% |
| Valuation | |||||
| P/E | 106.29 | 106.29 | 113.47 | 147.50 | — |
| EV/EBITDA | 45.38 | 45.38 | 59.70 | 81.55 | — |
| P/B | 4.42 | 4.42 | 5.38 | 8.88 | 9.80 |
| Growth & Yield | |||||
| Revenue Growth | 12.1% | 12.1% | -4.9% | 13.6% | — |
| EPS Growth | -13.3% | -13.3% | -16.7% | 135.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
116.6%
EPS terminal req.
$1.32
Spread vs growth
-129.9%
5Y implied EPS CAGR
65.2%
EPS terminal req.
$1.60
Spread vs growth
-78.5%
10Y implied EPS CAGR
34.8%
EPS terminal req.
$2.57
Spread vs growth
-48.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-30.3%
Start / end P/E
142.3x → 114.5x
EPS bridge
0.15 → 0.13
Residual
+2.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.